Cargando…
Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation
BACKGROUND: Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels is strongly associated with cardiac extracellular matrix accumulation and atrial fibrosis. Whether serum levels of TIMP-1 are associated with atrial fibrillation (AF) recurrence following radiofrequency catheter ablation (RFCA) rema...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606231/ https://www.ncbi.nlm.nih.gov/pubmed/36312240 http://dx.doi.org/10.3389/fcvm.2022.961914 |
_version_ | 1784818247317585920 |
---|---|
author | Li, Haiwei Sun, Weiping Wang, Zefeng Wang, Ziyu Du, Xiao Chen, Junjun Gao, Jianwei Liu, Xuxia Wang, Xipeng Wang, Yueli Wu, Yongquan Zhang, Xiaoping |
author_facet | Li, Haiwei Sun, Weiping Wang, Zefeng Wang, Ziyu Du, Xiao Chen, Junjun Gao, Jianwei Liu, Xuxia Wang, Xipeng Wang, Yueli Wu, Yongquan Zhang, Xiaoping |
author_sort | Li, Haiwei |
collection | PubMed |
description | BACKGROUND: Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels is strongly associated with cardiac extracellular matrix accumulation and atrial fibrosis. Whether serum levels of TIMP-1 are associated with atrial fibrillation (AF) recurrence following radiofrequency catheter ablation (RFCA) remains unknown. MATERIALS AND METHODS: Serum TIMP-1 levels of patients with AF before they underwent initial RFCA were measured using ELISA. Univariate and multivariate-adjusted Cox models were constructed to determine the relationship between TIMP-1 levels and AF recurrence. Multivariate logistic regression analyses were performed to determine predictors of AF recurrence. RESULTS: Of the 194 enrolled patients, 61 (31.4%) had AF recurrence within the median 30.0 months (interquartile range: 16.5–33.7 months) of follow-up. These patients had significantly higher baseline TIMP-1 levels than those without AF recurrence (129.8 ± 65.7 vs. 112.0 ± 51.0 ng/ml, P = 0.041). The same was true of high-sensitivity C-reactive protein (3.9 ± 6.0 vs. 1.9 ± 2.8 ng/ml, P = 0.001). When a TIMP-1 cutoff of 124.15 ng/ml was set, patients with TIMP-1 ≥ 124.15 ng/ml had a higher risk of recurrent AF than those with TIMP-1 < 124.15 ng/ml (HR, 1.961, 95% CI, 1.182–2. 253, P = 0.009). Multivariate Cox regression analysis revealed that high TIMP-1 was an independent risk factor for AF recurrence. Univariate Cox regression analysis found that substrate modification surgery does not affect AF recurrence (P = 0.553). Subgroup analysis revealed that female sex, age < 65 years, hypertension (HTN), body mass index (BMI) ≥ 24 kg/m(2), CHA2DS2-VASc score < 2, HAS-BLED score < 3, and EHRA score = 3 combined with high TIMP-1 level would perform well at predicting AF recurrence after RFCA. CONCLUSION: Elevated preoperative TIMP-1 levels are related to a higher risk of AF recurrence and can independently predict AF recurrence following RFCA. |
format | Online Article Text |
id | pubmed-9606231 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-96062312022-10-28 Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation Li, Haiwei Sun, Weiping Wang, Zefeng Wang, Ziyu Du, Xiao Chen, Junjun Gao, Jianwei Liu, Xuxia Wang, Xipeng Wang, Yueli Wu, Yongquan Zhang, Xiaoping Front Cardiovasc Med Cardiovascular Medicine BACKGROUND: Tissue inhibitor of metalloproteinase-1 (TIMP-1) levels is strongly associated with cardiac extracellular matrix accumulation and atrial fibrosis. Whether serum levels of TIMP-1 are associated with atrial fibrillation (AF) recurrence following radiofrequency catheter ablation (RFCA) remains unknown. MATERIALS AND METHODS: Serum TIMP-1 levels of patients with AF before they underwent initial RFCA were measured using ELISA. Univariate and multivariate-adjusted Cox models were constructed to determine the relationship between TIMP-1 levels and AF recurrence. Multivariate logistic regression analyses were performed to determine predictors of AF recurrence. RESULTS: Of the 194 enrolled patients, 61 (31.4%) had AF recurrence within the median 30.0 months (interquartile range: 16.5–33.7 months) of follow-up. These patients had significantly higher baseline TIMP-1 levels than those without AF recurrence (129.8 ± 65.7 vs. 112.0 ± 51.0 ng/ml, P = 0.041). The same was true of high-sensitivity C-reactive protein (3.9 ± 6.0 vs. 1.9 ± 2.8 ng/ml, P = 0.001). When a TIMP-1 cutoff of 124.15 ng/ml was set, patients with TIMP-1 ≥ 124.15 ng/ml had a higher risk of recurrent AF than those with TIMP-1 < 124.15 ng/ml (HR, 1.961, 95% CI, 1.182–2. 253, P = 0.009). Multivariate Cox regression analysis revealed that high TIMP-1 was an independent risk factor for AF recurrence. Univariate Cox regression analysis found that substrate modification surgery does not affect AF recurrence (P = 0.553). Subgroup analysis revealed that female sex, age < 65 years, hypertension (HTN), body mass index (BMI) ≥ 24 kg/m(2), CHA2DS2-VASc score < 2, HAS-BLED score < 3, and EHRA score = 3 combined with high TIMP-1 level would perform well at predicting AF recurrence after RFCA. CONCLUSION: Elevated preoperative TIMP-1 levels are related to a higher risk of AF recurrence and can independently predict AF recurrence following RFCA. Frontiers Media S.A. 2022-10-13 /pmc/articles/PMC9606231/ /pubmed/36312240 http://dx.doi.org/10.3389/fcvm.2022.961914 Text en Copyright © 2022 Li, Sun, Wang, Wang, Du, Chen, Gao, Liu, Wang, Wang, Wu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cardiovascular Medicine Li, Haiwei Sun, Weiping Wang, Zefeng Wang, Ziyu Du, Xiao Chen, Junjun Gao, Jianwei Liu, Xuxia Wang, Xipeng Wang, Yueli Wu, Yongquan Zhang, Xiaoping Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation |
title | Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation |
title_full | Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation |
title_fullStr | Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation |
title_full_unstemmed | Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation |
title_short | Higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation |
title_sort | higher serum tissue inhibitor of metalloproteinase-1 predicts atrial fibrillation recurrence after radiofrequency catheter ablation |
topic | Cardiovascular Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606231/ https://www.ncbi.nlm.nih.gov/pubmed/36312240 http://dx.doi.org/10.3389/fcvm.2022.961914 |
work_keys_str_mv | AT lihaiwei higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT sunweiping higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT wangzefeng higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT wangziyu higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT duxiao higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT chenjunjun higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT gaojianwei higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT liuxuxia higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT wangxipeng higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT wangyueli higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT wuyongquan higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation AT zhangxiaoping higherserumtissueinhibitorofmetalloproteinase1predictsatrialfibrillationrecurrenceafterradiofrequencycatheterablation |